FdaApplication
NDA 204569
Identifiers
- fda_app_no: NDA204569
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP |
| application_type | NDA |
| approval_date | 2014-08-13 |
Revenue by product
BELSOMRA
| Period | Revenue |
|---|---|
| Q4 2025 | $49.0M |
| Q3 2025 | $47.0M |
| Q2 2025 | $40.0M |
| Q1 2025 | $50.0M |
| Q4 2024 | $45.0M |
| Q3 2024 | $78.0M |
| Q2 2024 | $53.0M |
| Q1 2024 | $46.0M |
| Q4 2023 | $55.0M |
| Q3 2023 | $58.0M |
| Q2 2023 | $63.0M |
| Q1 2023 | $56.0M |
| Q4 2022 | $59.0M |
| Q3 2022 | $62.0M |
| Q2 2022 | $69.0M |
| Q1 2022 | $69.0M |
| Q4 2021 | $80.0M |
| Q3 2021 | $81.0M |
| Q2 2021 | $78.0M |
| Q1 2021 | $79.0M |
| Q4 2020 | $83.0M |
| Q3 2020 | $81.0M |
| Q2 2020 | $84.0M |
| Q1 2020 | $79.0M |
| Q4 2019 | $83.0M |
| Q3 2019 | $80.0M |
| Q2 2019 | $76.0M |
| Q1 2019 | $67.0M |
| Q4 2018 | $69.0M |
| Q3 2018 | $66.0M |
| Q2 2018 | $71.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BELSOMRA | SUVOREXANT | 20MG | TABLET;ORAL |
| BELSOMRA | SUVOREXANT | 5MG | TABLET;ORAL |
| BELSOMRA | SUVOREXANT | 15MG | TABLET;ORAL |
| BELSOMRA | SUVOREXANT | 10MG | TABLET;ORAL |
4 products